150 related articles for article (PubMed ID: 8492318)
1. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis.
Watson PH; Safneck JR; Le K; Dubik D; Shiu RP
J Natl Cancer Inst; 1993 Jun; 85(11):902-7. PubMed ID: 8492318
[TBL] [Abstract][Full Text] [Related]
2. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
3. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
4. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer.
Borg A; Baldetorp B; Fernö M; Olsson H; Sigurdsson H
Int J Cancer; 1992 Jul; 51(5):687-91. PubMed ID: 1612775
[TBL] [Abstract][Full Text] [Related]
5. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.
Singhi AD; Cimino-Mathews A; Jenkins RB; Lan F; Fink SR; Nassar H; Vang R; Fetting JH; Hicks J; Sukumar S; De Marzo AM; Argani P
Mod Pathol; 2012 Mar; 25(3):378-87. PubMed ID: 22056952
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of c-myc proto-oncogene in primary human breast carcinomas.
Pavelic ZP; Steele P; Preisler HD
Anticancer Res; 1991; 11(4):1421-7. PubMed ID: 1660688
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
8. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
9. Comparative polymerase chain reaction analysis of c-myc amplification on archival breast fine-needle aspiration materials.
Rao JY; Apple SK; Jin Y; Lin S; Nieberg RK; Hirtschowitz SL
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):175-9. PubMed ID: 10698478
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of c-myc and CCNE2 amplification in breast cancer with quantitative multi-gene fluorescence in-situ hybridization].
Li Z; Meng Q; Yu Q; Zhou Z; Li L
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):455-8. PubMed ID: 25327794
[TBL] [Abstract][Full Text] [Related]
11. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
[TBL] [Abstract][Full Text] [Related]
13. C-myc oncogene amplification in ductal carcinoma in situ of the breast.
Aulmann S; Bentz M; Sinn HP
Breast Cancer Res Treat; 2002 Jul; 74(1):25-31. PubMed ID: 12150449
[TBL] [Abstract][Full Text] [Related]
14. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
16. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression.
Kawate S; Fukusato T; Ohwada S; Watanuki A; Morishita Y
Oncology; 1999; 57(2):157-63. PubMed ID: 10461064
[TBL] [Abstract][Full Text] [Related]
17. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
Corzo C; Corominas JM; Tusquets I; Salido M; Bellet M; Fabregat X; Serrano S; Solé F
Cancer Genet Cytogenet; 2006 Mar; 165(2):151-6. PubMed ID: 16527609
[TBL] [Abstract][Full Text] [Related]
18. Identification of high-risk breast cancer patients from genetic changes of their tumors.
Watatani M; Inui H; Nagayama K; Imanishi Y; Nishimura K; Hashimoto Y; Yamauchi E; Hojo T; Kotsuma Y; Yamato M; Matsunami N; Yasutomi M
Surg Today; 2000; 30(6):516-22. PubMed ID: 10883462
[TBL] [Abstract][Full Text] [Related]
19. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.
Blancato J; Singh B; Liu A; Liao DJ; Dickson RB
Br J Cancer; 2004 Apr; 90(8):1612-9. PubMed ID: 15083194
[TBL] [Abstract][Full Text] [Related]
20. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma.
Soini Y; Mannermaa A; Winqvist R; Kamel D; Poikonen K; Kiviniemi H; Pääkkö P
J Histochem Cytochem; 1994 Jun; 42(6):795-803. PubMed ID: 7910618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
